Eli Lilly (LLY) Q4 revenue jumped 43% to $19.3B. Mounjaro sales surged 110% to $7.4B. Novo Nordisk (NVO) expects sales to decline 5% to 13% in 2026 due to pricing pressures and patent losses. Lilly’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results